DoD Gulf War Illness, Clinical Evaluation Award
The FY21 GWIRP Clinical Evaluation Award supports translation of validated GWI research, including qualified and replicated preclinical findings, to a Gulf War Veteran population. The Clinical Evaluation Award targets the Verification phase of the research pipeline as outlined in Section II.A.2. Statistically powered biomarker trials with the potential to validate use of biomarkers as clinical endpoints or proof-of-concept intervention trials (e.g., pilot, first in human, phase 1-2a) are encouraged under this funding opportunity. Clinical trials may be designed to evaluate pharmacologic agents (drugs or biologics), devices, clinical guidance or other approaches, and technologies supported by strong objective evidence in the GWI field. While studies of treatments repurposed from other disorders sharing GWI symptomatology will be considered (with appropriate rationale), the FY21 GWIRP encourages studies that translate qualified results from the GWI research community. Biomarker invest...